Moexipril for Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid
| Autor: | Keith D. Lindor, Janice L. Petz, Jayant A. Talwalkar, Roberta A. Jorgensen, Phunchai Charatcharoenwitthaya, Andrea A. Gossard, Jill C. Keach, Paul Angulo |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Cholagogues and Choleretics medicine.medical_specialty Physiology medicine.drug_class Bilirubin Administration Oral Angiotensin-Converting Enzyme Inhibitors Moexipril Gastroenterology chemistry.chemical_compound Primary biliary cirrhosis Tetrahydroisoquinolines Internal medicine medicine Humans Aspartate Aminotransferases Aged Dose-Response Relationship Drug Bile acid Liver Cirrhosis Biliary business.industry Ursodeoxycholic Acid Middle Aged Hepatology Alkaline Phosphatase medicine.disease Angiotensin II Ursodeoxycholic acid Treatment Outcome Endocrinology chemistry Delayed-Action Preparations Quality of Life Alkaline phosphatase Female business medicine.drug |
| Zdroj: | Digestive Diseases and Sciences. 55:476-483 |
| ISSN: | 1573-2568 0163-2116 |
| DOI: | 10.1007/s10620-009-0744-1 |
| Popis: | Blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We evaluated the safety and efficacy of moexipril, an angiotensin-converting enzyme inhibitor, in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA). Twenty PBC patients on UDCA (13-15 mg/kg/day) therapy with an elevation of serum alkaline phosphatase at least twice the upper limit of normal were treated with oral moexipril 15 mg/day for one year. No significant changes in serum alkaline phosphatase (379 +/- 32 vs. 379 +/- 51), bilirubin (0.8 +/- 0.1 vs. 0.9 +/- 0.1), aspartate aminotransferase (60 +/- 8 vs. 63 +/- 9), and Mayo risk score (3.55 +/- 0.2 vs. 3.62 +/- 0.2) was associated with the treatment. Fatigue and health-related quality of life scores during treatment demonstrated a trend toward improvement. Moexipril was not clinically beneficial to PBC patients responding suboptimally to UDCA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink